key: cord-0845041-22vxqt0q
authors: Patel, Priya; Ruge, Max; Gomez, Joanne Michelle D.; du Fay de Lavallaz, Jeanne; Rao, Anupama; Williams, Kim A.; Volgman, Annabelle Santos; Costanzo, Maria Rosa R.; Suboc, Tisha; Marinescu, Karolina
title: Prognostic value of H(2)FPEF score in COVID-19
date: 2022-03-02
journal: Am Heart J Plus
DOI: 10.1016/j.ahjo.2022.100111
sha: 60894d6137b2f42a9099c301f98385558f5b81e7
doc_id: 845041
cord_uid: 22vxqt0q

STUDY OBJECTIVE: This study sought to assess the predictive value of H(2)FPEF score in patients with COVID-19. DESIGN: Retrospective study. SETTING: Rush University Medical Center. PARTICIPANTS: A total of 1682 patients had an echocardiogram in the year preceding their COVID-19 admission with a preserved ejection fraction (≥50%). A total of 156 patients met inclusion criteria. INTERVENTIONS: Patients were divided into H(2)FPEF into low (0–2), intermediate (3–5), and high (6–9) score H(2)FPEF groups and outcomes were compared. MAIN OUTCOME MEASURES: Adjusted multivariable logistic regression models evaluated the association between H(2)FPEF score group and a composite outcome for severe COVID-19 infection consisting of (1) 60-day mortality or illness requiring (2) intensive care unit, (3) intubation, or (4) non-invasive positive pressure ventilation. RESULTS: High H(2)FPEF scores were at increased risk for severe COVID-19 infection when compared intermediate to H(2)FPEF score groups (OR 2.18 [CI: 1.01–4.80]; p = 0.049) and low H(2)FPEF score groups (OR 2.99 [CI: 1.22–7.61]; p < 0.05). There was no difference in outcome between intermediate H(2)FPEF scores (OR 1.34 [CI: 0.59–3.16]; p = 0.489) and low H(2)FPEF score. CONCLUSIONS: Patients with a high H(2)FPEF score were at increased risk for severe COVID-19 infection when compared to patients with an intermediate or low H(2)FPEF score regardless of regardless of coronary artery disease and chronic kidney disease.

The coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly grown into a global pandemic with a surge in hospitalizations and deaths. COVID-19 can present with a wide spectrum of symptoms ranging from mild symptoms to acute respiratory distress syndrome (ARDS), septic shock, and multiorgan failure. In addition to respiratory complications, recent reports suggest that 20-25% of patients will suffer from cardiac complications 1 and that patients with pre-existing cardiovascular disease are at even higher risk of severe COVID-19 infection and death [2] [3] [4] [5] [6] [7] [8] .

Given the rising proportion of HFpEF hospitalizations in the United States 9 and the scarcity of current information 10, 11 , it would be helpful to explore the relationship between COVID- 19 and HFpEF. It has been suggested that COVID-19 may cause exacerbation of HFpEF through direct mechanisms such as viral infiltration, inflammation, or cardiac fibrosis but also unmask subclinical HFpEF or promote the development of new HFpEF 12 . This paucity of studies examining the relationship between HFpEF and COVID-19 could partly be due to the challenges in diagnosing HFpEF. The H 2 FPEF score was developed as a tool to address the diagnostic difficulty in discriminating exertional dyspnea due to HFpEF from non-cardiac causes. The weighted score, as seen in Table 1 , is based on 6 variables -"heavy" (obesity), treatment with ≥2 normal, >0.09 ng/mL at our hospital system), non-fatal stroke, and cardiac death. During this subsequent chart review, the electronic medical record was also assessed for patient readmission and mortality.

To be included in our cohort, patients must have (1) a TTE in the year before their COVID-19 admission and (2) had a normal left ventricular ejection fraction (EF) of greater than 50% on that TTE. H 2 FPEF scores were calculated using the previously published scoring system by Reddy et al., as summarized in Table 1 . Obesity was defined as BMI >30 kg/m 2 . Atrial fibrillation was determined from clinical history and ECG. The number of antihypertensives was determined using the list of the patient's ambulatory medications on the day of admission. The E/e' measurement is the ratio of early diastolic mitral inflow velocity to septal mitral annulus tissue relaxation velocity. The E/e' ratio and pulmonary artery systolic pressure were manually extracted from the most recent TTE completed within 1 year before the COVID admission date.

Patients were divided into three groups, a low, intermediate, and high score group consisting of H 2 FPEF scores from 0 -2, 3 -5, and 6 -9, respectively. The primary outcome of the study was a composite for severe COVID-19 infection consisting of (1) 60-day mortality or illness requiring (2) intensive care unit, (3) intubation, or (4) non-invasive positive pressure ventilation.

Due to the potential confounder that the cohort of patients that required a prior TTE may represent an overall sicker population at baseline, an additional analysis was performed by propensity score matching each H 2 FPEF score group (low, intermediate, and high) to a similar group lacking a prior TTE. Covariables for the propensity score matching were pre-defined and J o u r n a l P r e -p r o o f chosen using clinical experience and comorbidities known to have a worse prognosis in patients with COVID-19. For this additional analysis only, body mass index (1.4% of patients were missing BMI data) was imputed with linear regression modeling prior to matching. A logistic regression model was used to generate propensity scores, and matching was performed using a 2:1 nearest neighbor method with a caliper width of 0.20. The incidence of both 60-day mortality and the composite outcome was then compared between each matched group.

iii.

Both data and statistical analyses were performed with RStudio version 1.3 (Boston, Massachusetts). Propensity score matching was performed using the MatchIt package, and

Kaplan-Meier survival estimates were created and plotted using the survival and survminer packages.

Normally distributed continuous variables are reported with mean and standard deviation, while non-normally distributed variables are described with median and interquartile range. Figure 1 ).

Our total cohort that met inclusion criteria for this study consisted of 156 patients who had a TTE with preserved ejection fraction in the year leading up to their COVID-19 admission ( Figure 1 ). When H 2 FPEF scores were calculated, 40 patients (25.6%) had low scores (0 -2), 72

(46.2%) had intermediate scores (3 -5) , and 44 (28.2%) had high scores (6 -9).

The median age of our entire cohort was 59 years (interquartile range 46 -71). The higher score groups tended to be older with a prior history of atrial fibrillation, both of which are individual components of the H 2 FPEF score calculation (Table 2) Of the 156 patients included in the study, 71 (45.5%) had dyspnea as a presenting symptom for their hospitalization, while 80 patients did not. The presence or absence of dyspnea was not documented in 5 patients in the study cohort.

ii.

In the propensity score matching analysis to see how the 156 patients with a prior TTE who met our inclusion criteria compared to the 1451 patients without one within each H 2 FpEF group, a total of 436 patients were matched (Supplemental Table 1 ). After matching, each of the covariates had a standardized mean difference (SMD)<0.10, indicating well-balanced groups were generated. Once balanced with matching, there was no difference in the incidence of either the composite outcome or 60-day mortality in the low, intermediate, or high score group between those with versus without an echocardiogram.

J o u r n a l P r e -p r o o f i.

The Figure 2 ).

In comparing secondary outcomes, the high score group was at greatest risk of requiring the intensive care unit (50.0%), while the low score group was at the lowest risk (25.0%, p = 0.048; Table 4 ). There was no significant difference between the groups in mechanical ventilation requirements, in-hospital mortality, inpatient length of stay, and 60-day readmission among the low, intermediate, and high score groups. When comparing individual 60-day complications, the high score group was at the highest risk of acute heart failure exacerbation (11.4%, p = 0.009).

Otherwise, the incidence of other complications, including life-threatening arrhythmia, venous thromboembolism, and requiring renal replacement therapy, was similar across the groups.

Journal Pre-proof However, event counts were low within the individual outcomes. The occurrence of overall MACE between the groups was also not statistically different, with incidences of 5.0%, 6.9%, and 13.6% in the low, intermediate, and high score groups, respectively.

A high H 2 FPEF score of 6-9, indicating a greater than 90% probability of having HFpEF, was a predictor of severe COVID-19 infection, which included (1) 60-day mortality or illness requiring

(2) intensive care unit, (3) intubation, or (4) non-invasive positive pressure ventilation when compared to the low score group. To our knowledge, this study is the first to use the H 2 FPEF score, an estimator of the probability of a patient having HFpEF, to demonstrate the association of HFpEF and COVID-19 outcomes.

Emerging theories suggest that COVID-19 causes significant morbidity and mortality through direct mechanisms such as viral entry into cells and indirectly through cytokine storm, hypoxemia, immune system dysregulation, and increased procoagulant activity 14 

A high H 2 FPEF score of 6-9 was also a significant predictor for the occurrence of acute HF Derangements in fluid balance are partly due to the increased incidence of acute kidney injury and renal dysfunction reported in COVID-19 23 , as well as increased capillary permeability related to localized microvascular inflammation and oxidative stress on endothelial cells 24 . These contributors to worsening pulmonary hypertension can then potentiate right ventricular

The key limitation of this paper is the significantly different populations included in this study when compared to the original H 2 FPEF score manuscript by Reddy et al. While Reddy et al.   assessed patients with unexplained dyspnea, our study included patients admitted for COVID-19 with an echocardiogram within one year before admission, only 45.5% of whom had dyspnea as a symptom during their admission. Therefore, our study used a highly pre-selected group, which could alter the predictive ability of the H 2 FPEF score in estimating whether a patient has HFpEF or not.

Other limitations are also present in this study. First, our inclusion criteria likely led to an underestimation of COVID-19 patients with HFpEF who had not had recent TTEs and subclinical HFpEF patients with no echocardiogram on record. Second, we do not know the number of patients in our cohort who had a previous diagnosis of HFpEF though this can be a challenging diagnosis to make and is in part addressed by the H 2 FPEF score. Third, the inclusion of only hospitalized COVID-19 patients with HFpEF may have overestimated the incidence of severe COVID infection, 60-day complications, and overall MACE. Furthermore, readmission rates and post-discharge mortality were only captured for patients who had a subsequent hospitalization to a health care system in or around Chicago that also uses the EPIC electronic medical record. Lastly, the observed relationship between high H 2 FPEF score and outcomes may merely reflect the adverse effects of the individual score variables themselves and does not delineate which factors contribute and the extent of their contribution. Larger multicenter studies are required to verify and further elucidate the relationship. Severe COVID-19 infection defined as a composite of (1) 60-day mortality, (2) needing the intensive care unit, or requiring (3) intubation or (4) 

Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation

Heart failure and COVID-19

Considerations for Heart Failure Care During the COVID-19 Pandemic. JACC Heart Fail

COVID-19 and Heart Failure With Preserved Ejection Fraction

A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction

Cardiovascular complications in COVID

Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality

COVID-19 and Cardiovascular Disease. Circulation

H2FPEF Score as a Prognostic Value in HFpEF Patients

E/e' Ratio in Patients With Unexplained Dyspnea: Lack of Accuracy in Estimating Left Ventricular Filling Pressure. Circ Heart Fail

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation

Clinical review: Myocardial depression in sepsis and septic shock. Crit Care

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Vascular underpinning of COVID-19

Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E-Deficient Mice

A current review of COVID-19 for the cardiovascular specialist

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19